Deals this week: Abilita Bio, Tempus Labs, Novo Nordisk

2nd February 2017 (Last Updated February 2nd, 2017 18:30)

US-based bio-technology company Abilita Bio has signed a research agreement with an undisclosed pharmaceutical company, which will help to further validate the former’s proprietary Bio EMP protein evaluation platform.

US-based bio-technology company Abilita Bio has signed a research agreement with an undisclosed pharmaceutical company, which will help to further validate the former’s proprietary Bio EMP protein evaluation platform.

The two companies will accelerate the G protein-coupled receptor (GPCR) drug discovery and development under the agreement.

Tempus Labs, a company that provides technology to doctors for personalising cancer care, has signed an agreement with the University of Michigan to identify customised treatments for pancreatic cancer patients.

The company will provide genomic and transcriptomic sequencing and analysis for the pancreatic cancer patients being treated at the university using its machine learning platform.

Danish healthcare company Novo Nordisk and the University of Oxford have entered a research agreement for early stage research for the treatment of type 2 diabetes.

"Danish healthcare company Novo Nordisk and the University of Oxford have entered a research agreement for early stage research for the treatment of type 2 diabetes."

The company will set up a new research centre at the university with an investment of $144.25m, as part of the agreement.

Janssen Research & Development and ChemDiv have entered a multi-year agreement to identify potent hit series for a range of targets across numerous therapeutic areas.

Based in the US, Janssen Research & Development provides research and development services, while ChemDiv is a discovery and development contract research organisation also based in the US.

US-based pharmacology and systems biology services provider Applied BioMath has reached an agreement with bio-pharmaceutical company CytomX Therapeutics to enter a development agreement.

Under the agreement, the two companies will jointly develop a quantitative systems pharmacology (QSP) model of the latter’s Probody platform, which is useful in immuno-oncology.

Both companies involved in the transaction are based in the US.